Kirin Holdings Co. (OTCMKTS:KNBWY) Sees Significant Decline in Short Interest

Kirin Holdings Co. (OTCMKTS:KNBWY) was the target of a large decline in short interest during the month of August. As of August 31st, there was short interest totaling 28,981 shares, a decline of 62.7% from the August 15th total of 77,766 shares. Approximately 0.0% of the company’s stock are sold short. Based on an average daily trading volume, of 25,911 shares, the days-to-cover ratio is presently 1.1 days.

Analysts Set New Price Targets

Separately, Zacks Research downgraded shares of Kirin from a “hold” rating to a “strong sell” rating in a research report on Monday, August 31st. One analyst has rated the stock with a Sell rating, According to MarketBeat, the stock has a consensus rating of “Sell”.

Kirin Stock Performance

Shares of Kirin stock traded up $0.16 on Friday, hitting $18.17. The stock had a trading volume of 47,382 shares, compared to its average volume of 17,226. The stock has a market cap of $14.72 billion, a price-to-earnings ratio of 11.57 and a beta of -0.01. The company has a current ratio of 1.44, a quick ratio of 1.01 and a debt-to-equity ratio of 0.51. Kirin has a 52-week low of $14.01 and a 52-week high of $19.99. The company’s 50 day moving average price is $18.54 and its 200 day moving average price is $17.25.

Kirin (OTCMKTS:KNBWY) last released its quarterly earnings results on Friday, August 7th. The company reported $0.58 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.42 by $0.16. The firm had revenue of $4.08 billion for the quarter, compared to the consensus estimate of $3.87 billion. Kirin had a return on equity of 12.29% and a net margin of 7.79%. On average, research analysts anticipate that Kirin will post 1.34 EPS for the current year.

About Kirin

Kirin Holdings Company, Limited is a Japan-based company with businesses spanning alcoholic and nonalcoholic beverages, pharmaceuticals and health science. Its beverage operations include beer, wine, spirits, soft drinks, bottled water and other consumer products marketed under brands such as Kirin, Ichiban Shibori and Afternoon Tea.

The company’s pharmaceutical business is conducted primarily through Kyowa Kirin, which researches, develops and commercializes prescription medicines, including treatments in areas such as oncology, immunology and nephrology.